TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth.
Palit SA, Vis D, Stelloo S, Lieftink C, Prekovic S, Bekers E, Hofland I, Šuštić T, Wolters L, Beijersbergen R, Bergman AM, Győrffy B, Wessels LF, Zwart W, van der Heijden MS.
Palit SA, et al. Among authors: wolters l.
Elife. 2019 Dec 19;8:e47430. doi: 10.7554/eLife.47430.
Elife. 2019.
PMID: 31855178
Free PMC article.